Viva Biotech Holdings provided earnings guidance for the year ended December 31, 2019. For the period, the company expected that the revenue of the Group for the year ended December 31, 2019 will increase by more than 50% as compared to the corresponding period in 2018, and the net profit for the Year will increase by more than 180% as compared to the corresponding period in 2018. Such significant increases are mainly attributable to (1) the mutual contribution of innovative and twin drivers of cash-for-service (CFS) business and the equity-for-service (EFS) business; (2) rapid growth in customer number and contract orders and the continuing expansion of incubation portfolio companies; and (3) progress in the research and development and financing of incubation portfolio companies resulting in partial disposal of certain incubation portfolio companies.